MICROPORT (00853) announced the Q3 2025 financial results of its subsidiary Shanghai Microport Endovascular Medtech (Group) Co., Ltd. (688016.SH). The company reported operating revenue of approximately RMB1.015 billion, a year-on-year increase of 4.66%. Net profit attributable to shareholders was around RMB429 million, representing a 22.46% decline compared to the same period last year. Basic earnings per share stood at RMB3.54.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.